A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)

You are here

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE)

Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant brain tumor in adults and can be resistant to conventional therapies. The purpose of this Phase II study is to evaluate how well a recurrent glioblastoma or gliosarcoma tumor responds to one injection of DNX-2401, a genetically modified oncolytic adenovirus, when delivered directly into the tumor followed by the administration of intravenous pembrolizumab (an immune checkpoint inhibitor) given every three weeks for up to two years or until disease progression.

Principal Investigator: Rohan Ramakrishna, MD 
Contact: Marissa Michael,  mam4001@med.cornell.edu 
This trial is active, but no longer enrolling. More information about this trial is available on clinicaltrials.gov